Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Tumor Biology

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-015-4440-9PMID 26581908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer

  2015cited by this paper
• Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

  2014cited by this paper
• Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

  2014cited by this paper
• HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells

  2013cited by this paper
• Constructions of sex and intimacy after cancer: Q methodology study of people with cancer, their partners, and health professionals

  2013cited by this paper
• Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome

  2013cited by this paper
• Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models

  2013cited by this paper
• [Metformin, an antidiabetic molecule with anti-cancer properties].

  2013cited by this paper
• EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.

  2012cited by this paper
• Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

  2011cited by this paper
• Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

  2011cited by this paper
• Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

  2011cited by this paper
• HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

  2010cited by this paper
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  2010cited by this paper
• EGFR Signaling and Drug Discovery

  2010cited by this paper
• Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

  2010cited by this paper
• The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

  2010cited by this paper
• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

  2010cited by this paper
• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

  2010cited by this paper
• Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

  2009cited by this paper
• Metformin induces unique biological and molecular responses in triple negative breast cancer cells

  2009cited by this paper
• Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

  2008cited by this paper
• Insulin-lowering effects of metformin in women with early breast cancer.

  2008cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.

  2007cited by this paper
• Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

  2007cited by this paper
• Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

  2007cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• "To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function.

  2006cited by this paper
• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

  2006cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• Medicine. Cancer-suppressing enzyme adds a link to type 2 diabetes.

  2005cited by this paper
• Cancer-Suppressing Enzyme Adds a Link to Type 2 Diabetes

  2005cited by this paper
• The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.

  2005cited by this paper
• Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones

  2004cited by this paper
• The ErbB receptors and their role in cancer progression.

  2003cited by this paper
• Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells

  2002cited by this paper
• Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.

  2002cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

  1996cited by this paper
• Nuclear receptor coactivators and corepressors.

  1996cited by this paper
• Tamoxifen resistance in breast cancer.

  1993cited by this paper
• Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

  1992cited by this paper
• Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.

  1991cited by this paper
• Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid.

  1988cited by this paper
• Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma.

  1987cited by this paper

• Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines

  2024cites this paper
• Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo

  2023cites this paper
• Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis

  2022cites this paper
• Association of diabetes and breast cancer characteristics at diagnosis

  2022cites this paper
• RETRACTED: Metformin and Breast Cancer: Where Are We Now?

  2022cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients

  2021cites this paper
• Type 2 Diabetes Mellitus and Clinicopathological Tumor Characteristics in Women Diagnosed with Breast Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer

  2020cites this paper
• The Chemosensitizing Role of Metformin in Anticancer Therapy.

  2020cites this paper
• Metformin inhibits human spermatozoa motility and signalling pathways mediated by protein kinase A and tyrosine phosphorylation without affecting mitochondrial function.

  2019cites this paper
• Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling

  2018cites this paper
• A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

  2018cites this paper
• Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways

  2018cites this paper
• Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway.

  2017cites this paper
• Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway

  2017cites this paper
• Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines

  2016cites this paper